189 related articles for article (PubMed ID: 37864031)
1. Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
Bai Y; Zhou L; Zhang C; Guo M; Xia L; Tang Z; Liu Y; Deng S
Oncogene; 2023 Dec; 42(49):3605-3618. PubMed ID: 37864031
[TBL] [Abstract][Full Text] [Related]
2. miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell Lung Cancer by Inhibiting CCND1.
Wang WH; Zhan JM; Tang YL; Zhou N; Liu WY; Jiang DW
Chemotherapy; 2022; 67(2):110-122. PubMed ID: 35042223
[TBL] [Abstract][Full Text] [Related]
3. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
4. PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation.
Li Y; Huang J; Zeng B; Yang D; Sun J; Yin X; Lu M; Qiu Z; Peng W; Xiang T; Li H; Ren G
Cancer Lett; 2018 Aug; 430():109-122. PubMed ID: 29777785
[TBL] [Abstract][Full Text] [Related]
5. Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.
Matsuyama Y; Suzuki M; Arima C; Huang QM; Tomida S; Takeuchi T; Sugiyama R; Itoh Y; Yatabe Y; Goto H; Takahashi T
Mol Carcinog; 2011 Apr; 50(4):301-9. PubMed ID: 21465578
[TBL] [Abstract][Full Text] [Related]
6. Inhibition effect of oxyepiberberine isolated from Coptis chinensis franch. On non-small cell lung cancer based on a network pharmacology approach and experimental validation.
Zhang Y; Yao Y; Fu Y; Yuan Z; Wu X; Wang T; Hong Z; Yang Y; Wu H
J Ethnopharmacol; 2021 Oct; 278():114267. PubMed ID: 34087401
[TBL] [Abstract][Full Text] [Related]
7. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract][Full Text] [Related]
8.
Thongsom S; Racha S; Ei ZZ; Petsri K; Aksorn N; Chamni S; Panpuang V; Zou H; Chanvorachote P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674871
[TBL] [Abstract][Full Text] [Related]
9. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer.
Xiong S; Zheng Y; Jiang P; Liu R; Liu X; Qian J; Gu J; Chang L; Ge D; Chu Y
Br J Cancer; 2014 Jan; 110(2):353-62. PubMed ID: 24281003
[TBL] [Abstract][Full Text] [Related]
10. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
11. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Li C; Hu J; Li W; Song G; Shen J
Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
[TBL] [Abstract][Full Text] [Related]
12. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
13. Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach.
Tan HY; Ho VW; Chan YT; Zhang C; Wang N; Xia W; Feng Y
Pharmacol Res; 2020 May; 155():104415. PubMed ID: 31465829
[TBL] [Abstract][Full Text] [Related]
14. The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Liu Y; Wang S; Dong QZ; Jiang GY; Han Y; Wang L; Wang EH
Med Oncol; 2016 Mar; 33(3):22. PubMed ID: 26820570
[TBL] [Abstract][Full Text] [Related]
15. 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
Postiglione I; Chiaviello A; Aloj SM; Palumbo G
Cell Prolif; 2013 Aug; 46(4):382-95. PubMed ID: 23869760
[TBL] [Abstract][Full Text] [Related]
16. Metabolic gene NR4A1 as a potential therapeutic target for non-smoking female non-small cell lung cancer patients.
Sun R; Bao MY; Long X; Yuan Y; Wu MM; Li X; Bao JK
Thorac Cancer; 2019 Apr; 10(4):715-727. PubMed ID: 30806032
[TBL] [Abstract][Full Text] [Related]
17. Proteasome Inhibitors Diminish c-Met Expression and Induce Cell Death in Non-Small Cell Lung Cancer Cells.
Li Y; Dong S; Tamaskar A; Wang H; Zhao J; Ma H; Zhao Y
Oncol Res; 2020 Dec; 28(5):497-507. PubMed ID: 32580819
[TBL] [Abstract][Full Text] [Related]
18. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
[TBL] [Abstract][Full Text] [Related]
19. Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
Schlesser C; Meul T; Stathopoulos G; Meiners S
Biomolecules; 2022 May; 12(6):. PubMed ID: 35740881
[TBL] [Abstract][Full Text] [Related]
20. Use of proteasome inhibition in the treatment of lung cancer.
Schenkein DP
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
